I. Sklenar

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Miklos Pless, Karim Belhadj, Hans D. Menssen et al. · Clinical Cancer Research · 2004 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +13

Association of Symptomatic Human Infection with Toxoplasma gondii with Imbalance of Monocytes and Antigen-Specific T Cell Subsets

I. Sklenar, Terry C. Jones, Ş. Ş. Alkan et al. · The Journal of Infectious Diseases · 1986 · 48 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies

Hans‐Heinrich Wolf, S.V. Davies, Michael Borte et al. · Vox Sanguinis · 2003 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.

Salvatore Siena, Marco Bregni, L Bonsi et al. · PubMed · 1993 · 42 citations

Medicine, Hematology, Oncology +15

Effect of Various Doses of Intravenous Polyclonal IgG on in vivo Levels of 12 Pneumococcal Antibodies in Patients with Chronic Lymphocytic Leukaemia and Multiple Myeloma

I. Sklenar, Gerald Schiffman, Viggo Jønsson et al. · Oncology · 2009 · 41 citations

Pharmacy, Hematology, Immunology +16